+

WO2016006975A3 - Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof - Google Patents

Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof Download PDF

Info

Publication number
WO2016006975A3
WO2016006975A3 PCT/KR2015/007220 KR2015007220W WO2016006975A3 WO 2016006975 A3 WO2016006975 A3 WO 2016006975A3 KR 2015007220 W KR2015007220 W KR 2015007220W WO 2016006975 A3 WO2016006975 A3 WO 2016006975A3
Authority
WO
WIPO (PCT)
Prior art keywords
imidazotriazinone
novel
imidazopyrazinone
derivatives
imidazopyrazinone derivatives
Prior art date
Application number
PCT/KR2015/007220
Other languages
French (fr)
Other versions
WO2016006975A2 (en
Inventor
Jung Nyoung Heo
Hwan Jung LIM
Kwang Rok Kim
Kyung Jin Kim
Uk Il Kim
Hyung Tae Bang
Ji Hye Yoon
Original Assignee
St Pharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020150068368A external-priority patent/KR20160007347A/en
Application filed by St Pharm Co., Ltd. filed Critical St Pharm Co., Ltd.
Priority to US15/325,692 priority Critical patent/US10179785B2/en
Priority to EP15818456.4A priority patent/EP3166946A4/en
Publication of WO2016006975A2 publication Critical patent/WO2016006975A2/en
Publication of WO2016006975A3 publication Critical patent/WO2016006975A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase -related disease, which contains the same as an active ingredient.
PCT/KR2015/007220 2014-07-11 2015-07-10 Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof WO2016006975A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/325,692 US10179785B2 (en) 2014-07-11 2015-07-10 Imidazotriazinone or imidazopyrazinone derivatives, and use thereof
EP15818456.4A EP3166946A4 (en) 2014-07-11 2015-07-10 Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20140087799 2014-07-11
KR10-2014-0087799 2014-07-11
KR1020150068368A KR20160007347A (en) 2014-07-11 2015-05-15 Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
KR10-2015-0068368 2015-05-15

Publications (2)

Publication Number Publication Date
WO2016006975A2 WO2016006975A2 (en) 2016-01-14
WO2016006975A3 true WO2016006975A3 (en) 2016-07-21

Family

ID=55065061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/007220 WO2016006975A2 (en) 2014-07-11 2015-07-10 Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof

Country Status (1)

Country Link
WO (1) WO2016006975A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201639851A (en) * 2015-03-16 2016-11-16 大日本住友製藥股份有限公司 Bicyclic imidazolo derivative
CN107286169B (en) * 2016-04-05 2020-11-24 北京四环制药有限公司 Tankyrase inhibitors
CN106496056B (en) * 2016-10-18 2018-03-02 中国人民解放军63975部队 A kind of synthetic method of arylamides
WO2019131794A1 (en) * 2017-12-27 2019-07-04 公益財団法人がん研究会 Anticancer agent
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110768A1 (en) * 2012-01-26 2013-08-01 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
WO2013143663A1 (en) * 2012-03-28 2013-10-03 Merck Patent Gmbh Bicyclic pyrazinone derivatives
US20130331375A1 (en) * 2012-06-07 2013-12-12 Genentech, Inc. Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
US20130345215A1 (en) * 2012-06-07 2013-12-26 Genentech, Inc. Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
US20130345226A1 (en) * 2012-06-20 2013-12-26 Hoffmann-La Roche Inc. Pyrrolopyrazone inhibitors of tankyrase
KR20140051944A (en) * 2011-07-13 2014-05-02 노파르티스 아게 4-piperidinyl compounds for use as tankyrase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140051944A (en) * 2011-07-13 2014-05-02 노파르티스 아게 4-piperidinyl compounds for use as tankyrase inhibitors
WO2013110768A1 (en) * 2012-01-26 2013-08-01 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
WO2013143663A1 (en) * 2012-03-28 2013-10-03 Merck Patent Gmbh Bicyclic pyrazinone derivatives
US20130331375A1 (en) * 2012-06-07 2013-12-12 Genentech, Inc. Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
US20130345215A1 (en) * 2012-06-07 2013-12-26 Genentech, Inc. Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
US20130345226A1 (en) * 2012-06-20 2013-12-26 Hoffmann-La Roche Inc. Pyrrolopyrazone inhibitors of tankyrase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3166946A4 *

Also Published As

Publication number Publication date
WO2016006975A2 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
WO2016064082A3 (en) Novel aminoalkyl benzothiazepine derivative and use thereof
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
EP4342540A3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
WO2015200680A3 (en) Prmt5 inhibitors and uses thereof
HUE052332T2 (en) Heteroaryl derivative or a pharmaceutically acceptable salt thereof, a process for its preparation and a pharmaceutical composition containing them as an active ingredient for the prevention or treatment of diseases associated with PI3 kinases
JOP20180071A1 (en) CJ Healthcare Corporation
EP3613419A4 (en) Pharmaceutical composition containing indirubin derivative as active ingredient
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
EP4327880A3 (en) Solid state form of ribociclib succinate
PH12016502246B1 (en) Carboxamide derivatives
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
EA201692298A1 (en) DERIVATIVES OF CARBOXAMIDES
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
EA201691741A1 (en) PHARMACEUTICAL COMPOSITION
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX2019008338A (en) Pharmaceutical composition containing sulglycotide or pharmaceutically acceptable salt thereof for preventing or treating dry eye.
WO2015002755A3 (en) Compounds for the treatment of malaria
WO2015001541A3 (en) Pharmaceutical film composition
EP3248603A4 (en) Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient
WO2016020408A3 (en) Compounds for preventing ototoxicity
WO2016163818A3 (en) Pharmaceutical composition for preventing or treating arthritis or inflammatory disease containing 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15818456

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15325692

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2015818456

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015818456

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载